Small molecule anticancer drugs

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Intensive drug discovery efforts are underway to develop more selective cancer therapies.
• Advances in molecular understanding of cancer reveal new potential drug targets.
• Current challenges include confirming in vivo target specificity and managing dose-limiting toxicities.

Purpose of the Study:

• To review emerging molecular targets and drug candidates in cancer therapy.
• To highlight the progress and challenges of farnesyl transferase and cyclin-dependent kinase inhibitors.
• To identify potential new cancer therapies in preclinical development.

Main Methods:

• Review of ongoing clinical trials for novel cancer therapeutics.
• Analysis of preclinical research on molecular targets such as telomerase, MDM2, and c-Raf.
• Assessment of drug efficacy and toxicity data from early-phase trials.

Main Results:

• Farnesyl transferase inhibitors (R115777, L778123) entered Phase I with dose-limiting myelosuppression; R115777 showed antitumor activity.
• A broad-spectrum cyclin-dependent kinase (cdk) inhibitor, flavopiridol, is entering Phase II trials.
• Concerns exist regarding the in vivo target specificity of current broad-spectrum inhibitors.

Conclusions:

• Selective inhibitors targeting specific molecular pathways represent a promising direction in cancer drug discovery.
• Further development of selective cyclin-dependent kinase inhibitors is ongoing.
• Preclinical investigations into targets like telomerase, MDM2, and c-Raf may yield novel cancer therapies within five years.